The original masterpiece of canaloplasty. 

Like the Mona Lisa, there is only one original masterpiece of canaloplasty: iTrack™ Advance. 

A masterstroke of innovation, iTrack™ Advance can catheterize 360 degrees of the canal via a single intubation while titrating 100 or more microliters of OVD with a pressurized delivery mechanism – all with the advantage of an illuminated microcatheter. 

When it comes to canaloplasty, choose the original – not an imitation. 

Visit us in Chicago at the 2024 annual meeting of the American Academy of Ophthalmology (AAO), Exhibit #2300 (Hall A), to learn more.

What’s so nice about the iTrack™ Advance is the fact that we can control how much viscoelastic we’re pushing into Schlemm’s canal, and to see distension of the canal by up to two or three times.

I. Paul Singh, MD (USA)

iTrack™ Advance is designed for the canal.

Clinically proven^1 – 5 for nearly two decades, the 220-micron illuminated iTrack™ Advance microcatheter is completely fashioned by hand under microscope in our own labs in California. Designed to trace the curvature of the canal, the microcatheter comprises an internal guidewire mechanism, infusion line and optical fiber. It also features a proprietary hydrophilic coating to aid its passage through the canal.

iTrack™ Advance is designed for high volume, high pressure viscodilation. 

The iTrack™ Advance connects to the ViscoInjector™, an external OVD reservoir which enables the delivery of up to 100 microliters of OVD or more. Most importantly, the ViscoInjector™ delivers OVD via a pressurized mechanism designed to overcome stenosis of the canal and collector channels. It is this combination of high volume, high-pressure OVD delivery that achieves consistent IOP reduction in glaucoma patients.⁵

¹ Lewis RA, von Wolff K, Tetz M, Koerber N, Kearney JR, Shingleton BJ, Samuelson TW. Canaloplasty: Three-year results of circumferential viscodilation and tensioning of Schlemm canal using a microcatheter to treat open-angle glaucoma. J Cataract Refract Surg. 2011;37(4):682 – 690. Data available upon request

² Koerber N, Ondrejka S. 6‑Year Efficacy and Safety of iTrack Ab-Interno Canaloplasty as a Stand-Alone Procedure and Combined With Cataract Surgery in Primary Open Angle and Pseudoexfoliative Glaucoma. J Glaucoma. 2024 Mar 1;33(3):176 – 182.

³Gallardo MJ. 36-month effectiveness of ab-interno canaloplasty standalone versus combined with cataract surgery for the treatment of open-angle glaucoma. Ophthalmol Glaucoma. 2022:S2589-4196(22)00025 ‑4.

⁴ Khaimi MA, Dvorak JD, Ding K. An Analysis of 3‑Year Outcomes Following Canaloplasty for the Treatment of Open-Angle Glaucoma. J Ophthalmol. 2017;2017:2904272.

⁵ Khaimi MA, Koerber N, Ondrejka S, Gallardo MJ. Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter. Clin Ophthalmol. 2024 Jan 16;18:173 – 183

The iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.

(USA) The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures*. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

* The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.

(Global) The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.